AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01883830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gaming therapy (Xbox)
Study NCT01883830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic balance platform (Biodex)
Study NCT03683108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol and Carbossimetyl Beta Glucan
Description: Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.
Study NCT03683108 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
Study NCT04256070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and tele-consultation
Description: education and tele-consultation based on Watson's Human Care Theory
Study NCT03019822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LSD
Description: 100ug per os, single dose
Study NCT03019822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: 125mg per os, single dose
Study NCT03019822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amphetamine
Description: 40.3mg per os, single dose
Study NCT03019822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsules containing mannitol looking identical to the other drugs
Study NCT01955733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695500
Study NCT04782024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 7-Keto 50mg
Study NCT04782024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 7-Keto 25mg
Study NCT04782024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00733408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT00733408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00733408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT02965547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning equipment
Description: The RIPC consisted of 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm and other side thigh. This intervention was undertaken one time in total.
Study NCT02965547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous blood collection
Description: Nurses will collect intravenous blood 6ml twice(at baseline and 1h after RIPC).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
Study NCT02965547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dCA measurement
Description: Serial measurements of dCA were performed at 7 time points, baseline, 1h, 3h, 6h, 9h, 12h, 24h after RIPC.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
Study NCT04911530 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02415660 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Thoracic spinal manipulation
Description: All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
Study NCT02415660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation
Description: All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
Study NCT02415660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trigger point dry needling
Description: The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the deep cervical extensor muscles and/or the upper trapezius muscles using FDA approved (FDA regulation # 880.5580) disposable 0.2-0.3 x 40-50 mm stainless steel Seirin J-type needles (Seirin, Japan). Those subjects randomized to TDN will undergo this treatment.
Study NCT02415660 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cervical range of motion exercises
Description: The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
Study NCT02415660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cervical range of motion exercises
Description: The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
Study NCT02415660 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Posterior neck muscle activation exercise
Description: The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
Study NCT02415660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Posterior neck muscle activation exercise
Description: The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
Study NCT02415660 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Trigger point dry needling sham
Description: The sham group will receive a simulated TDN. Using a toothpick in a needle guide-tube, the investigator will tap, rest, and twist the toothpick for approximately 30 seconds in the same 2 muscles, 2 sites in each muscle. The sham treatment will not penetrate the skin.
Study NCT02415660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm
Description: A trained investigator will insert the needle through the participants skin into the deep cervical extensors and/or the upper trapezius muscles. Needles are FDA approved (#880.5580)
Study NCT02267811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthodontic Treatment
Description: Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
Study NCT02267811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse™
Description: Participants carry out daily OrthoPulse™ treatments at home.
Study NCT02652520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HEMO2Life® use in organ preservation solution
Description: The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
Study NCT04232124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypertension Management Model
Description: 1. Blood Pressure readings by barbers~2. Clinical Pharmacist evaluation and counseling~3. Blood pressure measurement~4. Point of care basic metabolic panel measurement
Study NCT02135471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acellular dermal matrix graft
Description: On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
Study NCT02135471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enamel matrix derivative
Description: On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
Study NCT03043131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte A
Description: Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
Study NCT03043131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer Lactate
Description: Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
Study NCT02917304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3110A vaccine
Description: 0.5mL, Intramuscular
Study NCT02301884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergen extract
Description: Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
Study NCT01694641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: time-lapse morphokinetic evaluation
Description: embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
Study NCT04492202 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The survey will be sent to health professionals via online link.
Study NCT02734355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80 mg and amlodipine 5 mg
Study NCT00878085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Therapy Device
Description: 3x a week for 4 weeks
Study NCT00878085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: 3x a week for 4 weeks
Study NCT03599024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCEA
Description: The patients were able to control the administration of analgesics by themselves.
Study NCT03599024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-PCEA
Description: The patients were receiving analgesics according to the physician's prescription.
Study NCT03599024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement
Description: All patients enrolled in the study were indicated for total hip replacement surgery.
Study NCT03599024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Description: All patients enrolled in the study were indicated for total hip replacement surgery.
Study NCT02976428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensor Guided Soft Tissue Balancing
Description: Primary TKR with soft tissue balancing with a sensor guided device.
Study NCT02976428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Soft Tissue Balancing
Description: Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
Study NCT03552315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbonated water with amino acids and chromium
Description: The active carbonated water containing amino acids and chromium picolinate is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
Study NCT03552315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Carbonated Water
Description: The placebo carbonated water is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
Study NCT04398498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: TruGraf® Testing
Description: 5 mL collection PAXgene blood sample
Study NCT01852110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7622
Description: MK-7622 capsule
Study NCT01852110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to MK-7622 capsule
Study NCT01852110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AChEI
Description: One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally
Study NCT04422041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time to discharge less than 24 hours
Description: Allow the joint medical discharge of the newborn together with its mother in less than 24 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
Study NCT04422041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discharge time between 24 and 48 hours
Description: Allow the joint medical discharge of the newborn together with its mother between 24-48 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
Study NCT02734355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for telmisartan and amlodipine)
Description: Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet
Study NCT01852110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AChEI
Description: One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally
Study NCT03876886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin 90mg/m2 iv d1 or divide into two days
Study NCT02559245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Descurainia Sophia
Study NCT02559245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ficus carica
Study NCT01045720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suo Quan Wan, Wu Lin San
Description: Suo Quan Wan Wu Lin San Placebo 2/daily
Study NCT01045720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (starch)
Study NCT01523860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Mitoxantrone, Bendamustine
Description: Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
Study NCT04666051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Application of fibrin glue sealant
Study NCT02674529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Selective Serotonin Reuptake Inhibitor (SSRI)
Study NCT03876886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide600mg/m2 iv d1,q14d\*4cycles;with G-CSF support: 3ug/kg ih
Study NCT03876886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel 175mg/m2 iv d1, q14d\*4cycles
Study NCT03876886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=3 iv d2, q14d\*8cycles;with G-CSF support: 3ug/kg ih
Study NCT03876886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 175mg/m2 iv d1, q14d\*8cycles
Study NCT03234478 — intervention group
Intervention type: OTHER
Intervention: cognitive assessments
Description: Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
Study NCT02831738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: Polydextrose 12 g
Study NCT02831738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Treatment
Description: no polydextrose
Study NCT00831740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech and Language Therapy (SLT)
Description: Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
Study NCT00831740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
Study NCT02359357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Study NCT02674529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02674529 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real-time Neurofeedback fMRI task pre- and post-RCT
Description: Placebo experiment during an fMRI scanning session
Study NCT02674529 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Real-time Neurofeedback fMRI task pre- and post-RCT
Description: Placebo experiment during an fMRI scanning session
Study NCT02891850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
Study NCT02891850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
Study NCT02891850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
Study NCT02422511 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomic sequencing
Description: Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
Study NCT00893555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: TDM (through level of 2-5mg/L).
Study NCT02422511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family history report
Description: Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
Study NCT02422511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family history report
Description: Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
Study NCT02924779 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Retrospective observational study
Study NCT00139399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Description: Patients were randomized to receive either a radial artery or a long saphenous vein graft to the left circumflex coronary artery territory during CABG surgery